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Kaposiform hemangioendothelioma (KHE) is a rare vascular tumor in children, which
can be accompanied by life-threatening thrombocytopenia, referred to as Kasabach-
Merritt phenomenon (KMP). The mTOR inhibitor sirolimus is emerging as targeted ther-
apy in KHE. As the sirolimus effect on KHE occurs only after several weeks, we aimed
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to evaluate whether additional transarterial embolization is of benefit for children with
KHE and KMP. Seventeen patients with KHE and KMP acquired from 11 hospitals in
Germany were retrospectively divided into two cohorts. Children being treated with
adjunct transarterial embolization and systemic sirolimus, and those being treated with
sirolimus without additional embolization. Bleeding grade as defined by WHO was
determined for all patients. Response of the primary tumor at 6 and 12 months
assessed by magnetic resonance imaging (MRI), time to response of KMP defined as
thrombocyte increase >150 × 103/μL, as well as rebound rates of both after cessation
of sirolimus were compared. N = 8 patients had undergone additive embolization to
systemic sirolimus therapy, sirolimus in this group was started after a mean of
6.5 ± 3 days following embolization. N = 9 patients were identified who had received
sirolimus without additional embolization. Adjunct embolization induced a more rapid
resolution of KMP within a median of 7 days vs 3 months; however, tumor response as
well as rebound rates were similar between both groups. Additive embolization may be
of value for a more rapid rescue of consumptive coagulopathy in children with KHE
and KMP compared to systemic sirolimus only.
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1 | INTRODUCTION
Kaposiform hemangioendothelioma (KHE) is a rare vascular tumor affect-
ing children with an incidence <0.1:100.000.1,2 KHE frequently manifests
as a rapidly growing mass of the skin and musculoskeletal system, infil-
trating adjacent tissues. In up to 70% KHE is complicated by a life-
threatening consumptive coagulopathy with severe thrombocytopenia:
Kasabach-Merritt phenomenon (KMP).1,3 Different from disseminated
intravascular coagulation (DIC), intratumoral platelet trapping through
activated endothelium carrying a partial lymphatic phenotype results in
severe thrombocytopenia.4 This intratumoral coagulopathy accounts for
a high mortality in KHE of 10% to 30% in KHE patients.5 As curative sur-
gical resection of KHE is frequently not possible and is additionally asso-
ciated with a high mortality,6 various systemic treatment options have
been suggested including corticosteroids, vincristine,7 interferon-alpha
and platelet inhibition.8,9 In 2013, a consensus document recommended
intravenous vincristine and either oral prednisolone or intravenous meth-
ylprednisolone as first-line treatment of KHE associated with KMP,10
while two more recent meta-analyses have identified vincristine as safer
and more effective compared to corticosteroids.7 Image-guided emboli-
zation has been shown to induce a rapid decrease of the tumor mass,
but the effect is considered to be only temporary.10,11 Besides the afore-
mentioned approaches, the mammalian target of rapamycin (mTOR)
inhibitor sirolimus, a substrate for CYP3A4, targeting the PI3K-Akt-
mTOR pathway is emerging as novel treatment option in KHE.12,13 While
traditionally used to inhibit the activation of T-lymphocytes in transplant
rejection, multiple reports have recently shown the efficiency of sirolimus
in treating both KHE and the associated KMP.14 In addition, sirolimus
seems equally effective for initial therapy15 and for steroid-resistant
KHE16 showing low rates of recurrence,17 although relapse after cessa-
tion of sirolimus treatment has been observed.18 Sirolimus treatment on
the one hand initiates shrinkage and remission of the tumor and similarly
it addresses KMP over time, leading to a normalization of thrombocyte
counts within a period of approximately 20 days.15-17,19
Therapy of complicated KHE thus aims at (a) remission of the pri-
mary tumor, (b) rapid resolution of the life-threatening consumptive
coagulopathy and (c) prevention of recurrence of either one. As
sirolimus is emerging as the most effective systemic approach to KHE
with good results in tumor remission, and as embolization has the
potential to rapidly resolve the severe intratumoral consumptive
coagulopathy by excluding the abnormal endothelium from the
What's new?
Kaposiform hemangioendothelioma (KHE) is a rare vascular
tumor in children. Up to 70% of these patients also develop
a life-threatening, consumptive coagulopathy known as
Kasabach-Merritt Phenomenon (KMP). Sirolimus is proving
to be an effective therapy for both KHE and KMP. However,
it can take several weeks for sirolimus to have an effect. In
this study, the authors found that initial treatment with
embolization provides a rapid rescue from the symptoms of
KMP. Image-guided, transarterial embolization may thus pro-
vide a valuable adjunct to sirolimus therapy of KHE/HMP.
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systemic circulation, we evaluated the added value of transarterial
embolization to systemic sirolimus in children with KHE/KMP in a ret-
rospective multicenter cohort.
2 | PATIENTS AND METHODS
2.1 | Study design
The study was performed as a retrospective analysis. Seventeen
patients with Kaposiform hemangioendothelioma were recruited from
11 German tertiary care hospitals from March 2012 to November
2019. Patients were divided into two groups: patients undergoing
embolization as additive treatment to systemic sirolimus and patients
receiving sirolimus without additional embolization.
2.2 | Patients and disease manifestation
Demographic, clinical, laboratory and procedural data were retrieved from
electronic patient records. Two of the patients reported have been previ-
ously published, including additional information about the cases.20,21
Clinical evaluation included assessment of tenderness of the lesion,
expansive character of the mass, skin temperature and discoloration, pul-
sations/AV-shunting, hemorrhage and associated lymphedema.
Bleeding grade associated with KHE was classified according to
the World Health Organization (WHO) scheme.22
2.3 | Treatment and response assessment
In patients receiving additive embolization, the procedure was carried
out under general anesthesia via a 4F groin access. Transarterial emboli-
zation was performed either using particles or ethylene vinyl alcohol
copolymer. The procedure was considered technically successful if
≥80% of the tumor vasculature was occluded at the end of the inter-
vention. Patients undergoing embolization underwent additional treat-
ment with weight-adapted acetylsalicylate acid, weight-adapted, from
2 to 20 mg/day for 6 months. Systemic sirolimus was given at a dose of
0.1 to 1.8 mg/kg/m2 to achieve serum levels of 4 to 15 ng/L.
Disease extent and therapy response were assessed on magnetic
resonance images (MRI). Response to therapy was specifically
assessed at 6 and 12 months after initiation of therapy, clinically as
well as by MRI. Similarly, blood tests were performed at respective
time points. Response to therapy was defined in two categories
(a) normalization of coagulopathy, defined as platelet increase
>150 × 103/μL and (b) response of KHE itself (graded as complete
response CR, partial response PR, stable disease SD and progressive
disease PD) according the Response Evaluation Criteria in Solid
Tumors. As KHE leaves residual scar tissue both at the skin and within
connective tissue, CR was defined as the absence of viable tumor on
contrast-enhanced MRI, without taking nonenhancing residual scar tis-
sue into account. Rebound of KHE and KMP after sirolimus
discontinuation was defined as a switch to progressive disease either
from SD, PR or CR after cessation of sirolimus treatment, defined
either by an increase in tumor size or a decrease of platelet counts
<150 × 103/μL.
2.4 | Data analysis and statistics
Data are shown as mean ± SE, median or as relative percentages.
Group comparisons were performed between patients undergoing
sirolimus with additive embolization of KHE and patients receiving
sirolimus without additional image-guided embolization. Comparison
of demographic patient data was performed using Fisher's exact test
for qualitative data or, depending on normality of data, either
two-sample t-test or Mann-Whitney U test for quantitative data.
Response to therapy was compared similarly with Fisher's exact test
and Mann-Whitney U test. For comparison of response of KMP, median
time of thrombocyte count normalization was compared between the
two groups using Kaplan-Maier analysis and log-rank test. A P value
<.05 was considered significant. Analysis was performed using the Gra-
phPad Prism version 7 (GraphPad Software, San Diego, CA) as well as
SAS Version 9.4 for Windows (SAS Institute Inc, Cary, NC).
3 | RESULTS
3.1 | Patient demographics
In total, 17 children with KHE and accompanying KMP were identified
and included (11 male, 6 female) with no significant difference of sex
distribution between the groups (P = .131). Patients in the embolization
group (n = 8) were younger (11.3 ± 7 months vs 41.8 ± 19 months),
however with no statistical difference (P = .219). Histology was
obtained in 15 of 17 (88%) of cases. In the remaining two patients, the
diagnosis was evident from the clinical picture and laboratory findings,
thus histological assessment was omitted. A short case description of
each patient is presented in Supplementary Table 1.
Bleeding grades were classified according to the World Health
Organization (WHO) scale: no bleeding was reported in 1 patient,
Grade 1 in 2 patients, Grade 2 in 4 patients, Grade 3 in 10 patients
and Grade 4 in none of the patients. There was no significant differ-
ence between bleeding scores at baseline in patients with emboliza-
tion (25% Grade 1, 12.5% Grade 2 and 62.5% Grade 3) and patients
without embolization (11.1% Grade 1, 33.3% Grade 2, and 55.6%
Grade 3; P = .908). Median thrombocyte count at baseline was
38.5 × 103/μL in group of patients with adjunct embolization vs
36.0 × 103/μL in the group without additional embolization
(P = .408). Median fibrinogen levels at baseline were 132 mg/dL in
group of patients with adjunct embolization vs 122.5 mg/dL in the
group without additional embolization (P = .798). Median D-dimer
levels at baseline were 16.95 mg/L in group of patients with adjunct
embolization vs 18.15 mg/L in the group without additional emboli-
zation (P = .825).
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TABLE 1 Tumor response of kaposiform hemangioendothelioma
Sirolimus (N = 9) Sirolimus + embolization (N = 8) Total (N = 17)
N % N % N % P value
KHE remission after 6 months P = .1750
Missing 0 (0.0) 1 (12.5) 1 (5.9)
(1) PD 0 0.0 0 0.0 0 0.0 P = .2615 (CR vs PR/SD/PD)
(2) SD 1 11.1 0 0.0 1 6.3 P = 1.0000 (CR/PR vs SD/PD)
(3) PR 7 77.8 4 57.1 11 68.8
(4) CR 1 11.1 3 42.9 4 25.0
KHE remission after 12 months P = .1058
Missing 1 (11.1) 1 (12.5) 2 (11.8)
(1) PD 1 12.5 0 0.0 1 6.6 P = .1189 (CR vs PR/SD/PD)
(2) SD 0 0.0 0 0.0 0 0.0 P = 1.0000 (CR/PR vs SD/PD)
(3) PR 4 50.0 1 14.3 5 33.3 P = 1.0000 (CR/PR/SD vs PD)
(4) CR 3 37.5 6 85.7 9 60.0
Note: Tumor response of KHE to systemic sirolimus ± embolization was compared with respect to progressive disease (PD), stable disease (SD), partial
response (PR) and complete response (CR), without revealing statistically significant differences between the two cohorts.
F IGURE 1 Response of Kasabach-Merrit phenomenon. Laboratory course of thrombocyte counts (A), fibrinogen (B), and D-dimers (C) is
shown for children receiving adjunct embolization to systemic sirolimus (n = 8, right panels) compared with patients receiving sirolimus without
additive embolization (n = 9, left panels)
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3.2 | Treatment and response
Embolization was performed in n = 8/17 (47%) of the patients;
sirolimus without additional embolization was used in n = 9/17 (53%)
patients. Embolization with devascularization of >80% of tumor vas-
culature was technically successful in 100%, without major peri-
procedural complications, especially no arterial thrombosis or
dissection occurred. In 2 of 8 patients, two subsequent embolization
procedures were performed, while in 6 of 8 patients one treatment
cycle was sufficient to complete the procedure. Sirolimus was applied
with a mean dose of 0.46 ± 0.1 mg/kg/m2 and was given for 278
± 56 days in the embolization group, and with a mean dose of 0.58
± 0.2 mg/kg/m2 given for 434 ± 69 days in the group without emboli-
zation (P = .677 for dose, P = .107 for time period differences). In the
embolization group, sirolimus was started 6.5 ± 3 days following the
embolization procedure.
Tumor response to therapy revealed no statistically significant
differences between the two groups (Table 1), PR or CR was achieved
in a majority of patients (Supplementary Figure 1).
One patient had previously been treated by embolization only as
systemic therapy was initially refused by the parents. Embolization in
this case initially led to a rapid regression of KHE and immediate
release from KMP, however, with complete relapse of KHE together
with KMP after 3 months (Supplementary Figure 2).
Response of KMP differed between the two treatment regimens
with respect to thrombocyte counts, while fibrinogen and D-dimers
did not reveal marked differences (Figure 1A-C). Patients with addi-
tive embolization were faster to achieve a thrombocyte count of
150 × 103/μL than patients without embolization (HR = 0.39,
P-value log-rank = .061, Figure 2). The median time to normalization
occurred within the 7 to 14 days interval in patients treated with
embolization plus sirolimus and at the 3 months in patients treated
with sirolimus only. At 6 and 12 months, KMP had resolved in
patients with and without additive embolization. No major bleeding
event was reported for any patients in both groups after initiation of
therapy.
Rebound of KHE together with KMP after discontinuation of
sirolimus occurred in 0 of 8 patients in the embolization group and in
3 of 9 patients in the group without embolization (P = .200).
Overall, 2 of 8 patients in the embolization group died within
12 months: one child at 11.5 months after embolization and sirolimus
treatment, with initially good response, due to metastatic disease con-
firmed by autopsy (Patient 8). The child's death was attributed to con-
gestive heart failure at the age of 8 days, 6 days after embolization
and sirolimus initiation, before full effects of systemic therapy could
become effective. This death was attributed at least partially to the
high arteriovenous shunting of the KHE together with a patent ductus
arteriosus (Patient 3). In the latter case, emergency embolization was
performed as a rescue procedure; however, the child passed away on
the day after embolization. Mean follow-up was 667 ± 151 days in
patients with embolization and 1501 ± 361 days in patients without
additional embolization (P = .060).
4 | DISCUSSION
Kaposiform hemangioendothelioma is a rare vascular tumor in
infants associated with potentially life-threatening severe thrombo-
cytopenia.1-3 In KMP, pathologically activated intratumoral endothe-
lium causes local platelet and fibrinogen sequestration leading to
severe thrombocytopenia, with or without lowered fibrinogen and
altered
D-dimers levels.4,23 In 2013, a consensus document recommended
intravenous vincristine together with oral prednisolone as the treat-
ment of choice in KHE presenting with KMP,10 with the positive
effect of vincristine confirmed in a large meta-analysis.7 In recent
years, sirolimus has emerged as a potent agent in KHE. Retrospec-
tive multicenter studies recommend sirolimus as a potential first-line
treatment alone or as part of a multimodal approach.14 Sirolimus has
been shown to provide recovery from life-threatening KMP after a
period of 3 weeks of oral application.15-17,19 With respect to this
period of severe coagulopathy, our aim was to evaluate whether
F IGURE 2 Kaplan-Meier analysis of
thrombocyte course after initiation of
therapy. To compare response of
consumptive coagulopathy time periods
where compared between start of
therapy until patients exceeded a
thrombocyte count >150 × 103/μL.
Hazard ratio of children receiving
sirolimus without additive embolization
was 0.39 compared with children
undergoing additive embolization (P value
log-rank .061)
BRILL ET AL. 5
transarterial embolization in adjunct to sirolimus treatment provides
a more rapid resolution of KMP and has a potential effect on tumor
outcome.
Our results suggest that KMP resolution occurs more rapidly after
embolization plus sirolimus; however, tumor response was similar
between both treatment regimens. Interestingly in the cohort of chil-
dren receiving sirolimus without embolization, 3 of 9 patients suffered
rebound of KHE/KMP within a 1-year period, whereas in the com-
bined treatment group no rebound was observed.
Transarterial embolization has been used in the past to treat KHE
and KMP, although most reports similarly use embolization only in
combination with systemic chemotherapy, mostly vincristine.11,24
Embolization alone seems to be associated with a high relapse rate of
KHE. Of note, one patient in our cohort had initially been treated by
embolization alone leading initially to a rapid regression of KHE and
immediate release from KMP; however, complete relapse of KHE
together with KMP occurred after 3 months. In our cohort, emboliza-
tion was technically successful in all patients and with exception of
two patients, only a single treatment cycle was required to rapidly res-
cue children from KMP. Embolization may therefore bridge the gap
between occurrence of life-threatening KMP and the effect of sys-
temic treatment. In our study, embolization was regularly combined
with platelet function inhibition by ASA, which may exert two differ-
ent effects in this scenario. On the one hand, platelet inhibition may
reduce intralesional platelet sequestration. On the other hand, chil-
dren with consumptive coagulopathy appear to have a hyperplastic
bone marrow, as evidenced by the rapid endogenous increase of
thrombocytes within a few days after embolization. Thrombocytope-
nia may thereby potentially switch into thrombophilia following
embolization and ASA can potentially counteract this effect. Several
reports have demonstrated beneficial effects of platelet function inhi-
bition in KHE in combination therapies.8,9
Initially, vincristine was considered the chemotherapeutic agent
of choice for KHE, yet the beneficial effects of sirolimus are becom-
ing increasingly evident. Although chemotherapeutic agents such as
vincristine exert unspecific effects on KHE, somatic or mosaic muta-
tions of the PI3KCA gene provide a clear molecular rationale for
sirolimus treatment in KHE. Sirolimus seems to exert both antip-
roliferative and antiangiogenic/−lymphangiogenic effects by
inhibiting mTOR, a serine-threonine kinase regulated by PI3K.
Recent studies reported long-term follow-up after KHE treatment
with sirolimus. Wang et al report a follow-up period of 28 months
with only mild side effects and no report of recurrence.17 Although
previously dosing was calculated to achieve target sirolimus levels of
10 to 15 ng/L, our cohort applied significantly lower sirolimus dos-
ing. Similarly, other reports suggest that levels around 5 ng/L may be
sufficient for successful treatment of KHE.25 Decreased dose regi-
mens may explain the low rate of systemic side effects of sirolimus
reported in the vascular anomalies literature compared to its use in
transplantation medicine.
Our study is limited by the small cohort size and the retrospective
study design. Moreover, the patient cohort reported is heterogeneous
with regard to age and more importantly with respect to previous and
concomitant systemic treatments, which may all have impact on the
long-term outcome and recurrence rates. ASA treatment routinely
performed in the embolization group and not given in the non-
embolization cohort may cause additional bias; however, its influence
on tumor response is considered negligible. Overall, our study is lim-
ited in evidence but can serve as a hypothesis generating work. Fur-
ther studies are therefore requested to answer these questions with
more robust evidence. Of note, none of the patients without emboli-
zation experienced severe bleeding complications in the period prior
to platelet count normalization. Thus, the clinical benefit of additional
embolization is yet unknown and has to be weighed against the
potential risk of intraarterial embolization in small children. At this
point, embolization cannot be recommended routinely for KHE/KMP
treatment; however, if embolization is being performed for KMP, chil-
dren should be placed on systemic therapy right after to achieve a
sustained response.
In summary, our study suggests that transarterial embolization
may add to systemic sirolimus in the treatment of kaposiform
hemangioendothelioma and provides are more rapid resolution of
potentially life-threatening Kasabach-Merritt phenomenon. However,
in this small cohort no significant differences in resolution of KHE
itself were observed.
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